Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation · Astrocytoma IDH Mutant Grade 2 · Oligodendroglioma · Oligodendroglioma IDH-mutant and 1p/19q-codeleted · IDH-mutant Gliomas
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 140 (planned)
- Started
- Mar 2027
- Main results expected
- May 2029
- Fully finished
- Mar 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0
Measured over: From the date of randomization until the date of first documented disease progression, approximately 30 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07712757 · record last updated 2026-07-17 · checked 2026-11-09 15:47 UTC